Ventrus cream misses in Phase III anal fissure trial

Ventrus Biosciences Inc. (NASDAQ:VTUS) said thrice-daily 2% diltiazem cream ( VEN 307) missed the primary endpoint

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE